Evidence map›Paper›PMID 42755367›Full record

ArticleNucleic acids research2026

The molecular basis of ADP-ribose pyrophosphorylation by a phage PRPS-like enzyme in NAD+ reconstitution.

Mengxi Liu, Jingbo Ma, Qingqing Zhang, Shaoting Xu, Jing Chen, En Lin, Yunkun Wu, Hua Li, Biao Zhou, Lixia Chen

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengxi LiuInstitute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Jingbo MaState Key Laboratory of Respiratory Disease, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangzhou 510095, China.
Qingqing ZhangWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shaoting XuWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jing ChenWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
En LinWuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yunkun WuInstitute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Hua LiInstitute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.ORCID 0000-0003-1903-836X
Biao ZhouState Key Laboratory of Respiratory Disease, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangzhou 510095, China.
Lixia ChenInstitute of Digital Materia Medica and Structural Pharmacology, Fujian Key Laboratory of Chinese Materia Medica, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.

Funding

China Postdoctoral Science Foundation 2025M772866Key Medical Disciplines and Specialties Program of Guangzhou (Tuberculosis) 2025-2027Major Project of Guangzhou National Laboratory GZNL2024A01030National Key R&D Program of China 2022YFA1303500-002National Key R&D Program of China GZNL2024A01030National Natural Science Foundation of China 32501089National Natural Science Foundation of China 82341085
6 · The paper itself

Abstract

Depletion of cellular NAD+ is an increasingly recognized bacterial antiphage strategy, and many phages counter this pressure by rebuilding NAD+ from its cleavage products. In the NARP1 pathway, Adps converts ADP-ribose (ADPR) and ATP into ADPR-PP, the immediate substrate for Namat-dependent NAD+ synthesis, but how a phosphoribosyl pyrophosphate synthetase (PRPS)-like fold catalyzes this noncanonical reaction has been unknown. Here we report structures of phage Adps in apo, ADPR/ATP-bound pre-catalytic, and ADPR-PP/AMP-bound product states, supported by LC-MS activity assays, kinetics, and mutagenesis. The structures show that Adps uses a conserved interdomain groove to bind the ADPR acceptor, while a remodeled PP loop and catalytic β-hairpin create a donor site that positions the ATP β-γ pyrophosphate next to the distal ribose of ADPR. Lys185 moves toward the reaction center during the transition from substrate to product states, and its substitution abolishes ADPR-PP formation and impairs Adps-Namat-mediated rescue. Comparison with canonical PRPS enzymes indicates that Adps retained an ancestral acceptor-recognition surface while rewiring donor binding and regulatory elements. These findings define the molecular basis of phage ADPR pyrophosphorylation and illustrate how viral enzymes can repurpose conserved nucleotide-metabolic scaffolds to restore NAD+ during host immune attack.

Indexed as

Adenosine Diphosphate RiboseBacteriophagesNADViral ProteinsAdenosine TriphosphateADP-RibosylationKineticsModels, MolecularAdenosine Diphosphate RiboseAdenosine TriphosphateNADViral Proteins

Identifiers

PMID42755367
PMCPMC13586617

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.